Los Angeles Capital Management
DYN icon

Los Angeles Capital Management’s Dyne Therapeutics DYN Stock Holding History

Los Angeles Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1K Sell
612
-13,080
-96% -$226K ﹤0.01% 1919
2025
Q4 		$322K Buy
+13,692
New +$259K ﹤0.01% 1060

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Los Angeles Capital Management's DYN Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Dyne Therapeutics (DYN) stake by 96% in Q1 2026, selling an estimated $226K and leaving 612 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1919.

Los Angeles Capital Management first reported a position in DYN in Q4 2025 and has held it in 2 quarters since. The position peaked at $322K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Los Angeles Capital Management held 612 shares of Dyne Therapeutics worth $11.1K as of Q1 2026.
  • Los Angeles Capital Management sold 13,080 Dyne Therapeutics shares in Q1 2026, an estimated $226K.
  • Dyne Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1919 holding.
  • Los Angeles Capital Management first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Los Angeles Capital Management's Dyne Therapeutics position peaked at $322K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.